Basic Info

Common NameDexrazoxane(F04751)
2D Structure
Description

An antimitotic agent with immunosuppressive properties. Dexrazoxane, the (+)-enantiomorph of razoxane, provides cardioprotection against anthracycline toxicity. It appears to inhibit formation of a toxic iron-anthracycline complex. The Food and Drug Administration has designated dexrazoxane as an orphan drug for use in the prevention or reduction in the incidence and severity of anthracycline-induced cardiomyopathy.

FRCD IDF04751
CAS Number24584-09-6
PubChem CID71384
FormulaC11H16N4O4
IUPAC Name

4-[(2S)-2-(3,5-dioxopiperazin-1-yl)propyl]piperazine-2,6-dione

InChI Key

BMKDZUISNHGIBY-ZETCQYMHSA-N

InChI

InChI=1S/C11H16N4O4/c1-7(15-5-10(18)13-11(19)6-15)2-14-3-8(16)12-9(17)4-14/h7H,2-6H2,1H3,(H,12,16,17)(H,13,18,19)/t7-/m0/s1

Canonical SMILES

CC(CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2

Isomeric SMILES

C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2

WikipediaDexrazoxane
Synonyms
        
            (S)-4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione)
        
            Dexrazoxane
        
            24584-09-6
        
            Zinecard
        
            ICRF-187
        
            Cardioxane
        
            Dexrazoxano
        
            Dexrazoxanum
        
            Dextrorazoxane
        
            Dexrazoxanum [INN-Latin]
        
Classifies
                

                  
                    Predicted: Veterinary Drug
                  

                
        
Update DateNov 13, 2018 17:07

Chemical Taxonomy

KingdomOrganic compounds
SuperclassOrganic acids and derivatives
ClassCarboxylic acids and derivatives
SubclassAmino acids, peptides, and analogues
Intermediate Tree NodesAmino acids and derivatives
Direct ParentAlpha amino acids and derivatives
Alternative Parents
Molecular FrameworkAliphatic heteromonocyclic compounds
SubstituentsAlpha-amino acid or derivatives - Dioxopiperazine - N-alkylpiperazine - 1,4-diazinane - Piperazine - Carboxylic acid imide - Dicarboximide - Carboxylic acid imide, n-unsubstituted - Tertiary aliphatic amine - Tertiary amine - Organoheterocyclic compound - Azacycle - Organic nitrogen compound - Organooxygen compound - Organonitrogen compound - Amine - Organic oxygen compound - Hydrocarbon derivative - Organic oxide - Carbonyl group - Organopnictogen compound - Aliphatic heteromonocyclic compound
DescriptionThis compound belongs to the class of organic compounds known as alpha amino acids and derivatives. These are amino acids in which the amino group is attached to the carbon atom immediately adjacent to the carboxylate group (alpha carbon), or a derivative thereof.

Properties

Property NameProperty Value
Molecular Weight268.273
Hydrogen Bond Donor Count2
Hydrogen Bond Acceptor Count6
Rotatable Bond Count3
Complexity404
Monoisotopic Mass268.117
Exact Mass268.117
XLogP-1.4
Formal Charge0
Heavy Atom Count19
Defined Atom Stereocenter Count1
Undefined Atom Stereocenter Count0
Defined Bond Stereocenter Count0
Undefined Bond Stereocenter Count0
Isotope Atom Count0
Covalently-Bonded Unit Count1

ADMET

Model Result Probability
Absorption
Blood-Brain BarrierBBB+0.6387
Human Intestinal AbsorptionHIA+0.8518
Caco-2 PermeabilityCaco2-0.6144
P-glycoprotein SubstrateSubstrate0.8766
P-glycoprotein InhibitorInhibitor0.6576
Non-inhibitor0.9653
Renal Organic Cation TransporterNon-inhibitor0.7348
Distribution
Subcellular localizationLysosome0.5380
Metabolism
CYP450 2C9 SubstrateNon-substrate0.8399
CYP450 2D6 SubstrateNon-substrate0.7872
CYP450 3A4 SubstrateSubstrate0.5139
CYP450 1A2 InhibitorNon-inhibitor0.9458
CYP450 2C9 InhibitorNon-inhibitor0.8828
CYP450 2D6 InhibitorNon-inhibitor0.9348
CYP450 2C19 InhibitorNon-inhibitor0.7777
CYP450 3A4 InhibitorNon-inhibitor0.9666
CYP Inhibitory PromiscuityLow CYP Inhibitory Promiscuity0.9741
Excretion
Toxicity
Human Ether-a-go-go-Related Gene InhibitionWeak inhibitor0.9410
Non-inhibitor0.8929
AMES ToxicityNon AMES toxic0.9132
CarcinogensNon-carcinogens0.9077
Fish ToxicityLow FHMT0.6662
Tetrahymena Pyriformis ToxicityHigh TPT0.8421
Honey Bee ToxicityLow HBT0.8736
BiodegradationNot ready biodegradable0.9910
Acute Oral ToxicityIII0.7343
Carcinogenicity (Three-class)Warning0.5287

Model Value Unit
Absorption
Aqueous solubility-2.0191LogS
Caco-2 Permeability0.5037LogPapp, cm/s
Distribution
Metabolism
Excretion
Toxicity
Rat Acute Toxicity2.4267LD50, mol/kg
Fish Toxicity2.3102pLC50, mg/L
Tetrahymena Pyriformis Toxicity0.1128pIGC50, ug/L

References

TitleJournalDatePubmed ID
The iron chelator Dp44mT inhibits the proliferation of cancer cells but fails to protect from doxorubicin-induced cardiotoxicity in spontaneously hypertensive rats.Cancer Chemother Pharmacol2011 Nov21373894

Targets

General Function:
Ubiquitin binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks. Essential during mitosis and meiosis for proper segregation of daughter chromosomes. May play a role in regulating the period length of ARNTL/BMAL1 transcriptional oscillation (By similarity).
Gene Name:
TOP2A
Uniprot ID:
P11388
Molecular Weight:
174383.88 Da
Mechanism of Action:
The mechanism by which dexrazoxane exerts its cardioprotective activity is not fully understood. Dexrazoxane is a cyclic derivative of EDTA that readily penetrates cell membranes. Results of laboratory studies suggest that dexrazoxane is converted intracellularly to a ring-opened chelating agent that interferes with iron-mediated free radical generation thought to be responsible, in part, for anthracycline-induced cardiomyopathy.
References
  1. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [11752352 ]
General Function:
Protein kinase c binding
Specific Function:
Control of topological states of DNA by transient breakage and subsequent rejoining of DNA strands. Topoisomerase II makes double-strand breaks.
Gene Name:
TOP2B
Uniprot ID:
Q02880
Molecular Weight:
183265.825 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [17139284 ]